A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy
OPTimal Intervention for the Prevention of Radiation Dermatitis During Breast Cancer Post-Mastectomy Radiotherapy (OPTIC): A Parallel, Three-Arm, Phase II Open-Label Randomized Trial
The purpose of this study is to find out which of three standard skin care approaches works best to prevent a skin reaction called radiation dermatitis (redness, irritation, or breakdown of the skin) in people receiving radiation therapy after mastectomy.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Atif Khan, MD
- Telefoonnummer: 848-225-6334
- E-mail: khana7@mskcc.org
Studie Contact Back-up
- Naam: Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
- E-mail: choij3@mskcc.org
Studie Locaties
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Werving
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
Middletown, New Jersey, Verenigde Staten, 07748
- Werving
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
Montvale, New Jersey, Verenigde Staten, 07645
- Werving
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Werving
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
Harrison, New York, Verenigde Staten, 10604
- Werving
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
Rockville Centre, New York, Verenigde Staten, 11553
- Werving
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Contact:
- Isabelle Choi, MD
- Telefoonnummer: 646-449-1997
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have pathologically confirmed breast cancer.
- Patients will have an assigned sex of female at birth.
- Patients will have undergone mastectomy without breast reconstruction surgery or with immediate reconstruction using one or more of an expander, implant, or flap-based approach.
- Patients will have pathologic stage T1-3 N0-1 M0 disease with indication for comprehensive post-mastectomy radiotherapy to the ipsilateral chest wall and regional lymph node basins (axilla, SCV, IMN).
- Patient/LAR willing to sign and date consent form
- Age ≥ 18
- ECOG Performance Status of ≤ 2
Exclusion Criteria:
-
Patients with indication for escalated skin dose (dermal invasion, skin involvement, positive surgical margin).
-
Patients planned to receive a scar or chest wall, or other boost.
-
Patients planned to receive post-mastectomy radiotherapy using a hypofractionated regimen (ie., >2.0 Gy per fraction).
-
Patients who have a diagnosis of connective tissue disorder or collagen vascular disorder.
-
Patients who have an active rash in the cervical or thoracic region.
-
Patients taking systemic steroids >10 mg/day.
-
Patients on active antimicrobial treatment at the time of study enrollment.
-
Patients with a prior history of organ or bone marrow transplant.
-
Patients who are pregnant or nursing
-
Prior Treatment:
- Patients with prior history of radiotherapy to the neck, thorax or abdomen.
- Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, which must have resolved to Grade ≤2, alopecia, and other toxicities considered clinically nonsignificant and/or stable on supportive therapy as determined by the investigator).
-
Comorbid conditions:
o Active infection requiring parenteral antibiotic(s)
-
Concomitant Medications:
o Concurrent systemic therapy during the course are not allowed, including cytotoxic chemotherapy, immunotherapy, and targeted therapy. Last dose of these agents must be delivered at least 2 weeks prior to start of radiotherapy and not to be restarted until at least 2 weeks following completion of radiotherapy. Endocrine therapy, pembrolizumab, Herceptin, Perjeta, and Kadcyla are allowed. Concurrent oral steroid medications are not allowed.
-
Allergies:
- History of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm 1: Mometasone furoate
An ARD prevention strategy that has demonstrated the ability to reduce significant radiation dermatitis during breast radiotherapy is the topical application of corticosteroid creams, including mometasone and betametasone |
Mometasone Furoate 1% Cream is a topical corticosteroid cream |
|
Experimenteel: Arm 2: Mepitel Film
The use of barrier films such as Mepitel Film, Hydrofilm, and StrataXRT, has also been demonstrated to be effective in reducing the risk of clinically significant ARD. |
Mepitel Film is a transparent film with a contact layer with silicone adhesion. |
|
Experimenteel: Arm 3: Bacterial decolonization
Bacterial decolonization (BD) is a intervention that has been studied as an ARD prevention measure. |
Bacterial decolonization (BD) regimen involves a 5 day regimen of twice-daily intranasal mupirocin and chlorhexidine body cleansing Bacterial decolonization (BD) regimen involves a 5 day regimen of twice-daily intranasal mupirocin and chlorhexidine body cleansing |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of acute radiation dermatitis with most desquamation (ARD-MD)
Tijdsspanne: 12 months
|
To evaluate the rate of acute radiation dermatitis with moist desquamation (ARD-MD) using three acute radiation dermatitis (ARD) prevention strategies compared with historical rates using standard of care strategies in patients receiving post-mastectomy radiotherapy (PMRT). |
12 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Isabelle Choi, MD, Memorial Sloan Kettering Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 26-356
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .